ASTH vs LLY: fair value comparison
Astrana Health, Inc. and Eli Lilly and Company · Updated 2026-09-07
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, ASTH currently sits closer to the top of our discount ranking.
| ASTH | LLY | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $35.91 | $1,149.36 |
| 12-month range | $22.32–$49.81 | $862.86–$1,160.00 |
| Sector rank | #7 of 113 Healthcare | #11 of 113 Healthcare |
| Quality grade | D | D |
| Leverage | High | High |
| Margin trend | — | Expanding |
| Revenue growth | — | High |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | — |
| 52-week position | The lower-middle quarter | The top quarter |
Full single-stock breakdowns: ASTH fair value analysis · LLY fair value analysis